To explore whether antithrombotic medication may protect against cognitive decline, tests of verbal memory, attention, abstract reasoning, verbal fluency, and mental flexibility were administered to 405 men at risk of cardiovascular disease. These subjects were a subgroup of those who had been participating in a randomised double blind factorial trial of low dose aspirin (75 mg daily) and low intensity oral anticoagulation with warfarin (international normalised ratio of 1.5) at 35 general practices across the United Kingdom for at least five years, were at least 55 years old at trial entry, and had been randomly allocated to one of four groups: active warfarin and active aspirin, active warfarin and placebo aspirin, placebo warfarin and active aspirin, and double placebo. Verbal fluency and mental flexibility were significantly better in subjects taking antithrombotic medication than in subjects taking placebo. Aspirin may have contributed more than warfarin to any beneficial effect. These results provide tentative evidence that antithrombotic medication may protect cognitive function in men at risk of cardiovascular disease. (3 Neurol Neurosurg Psychiatry 1997;62:269-272) Keywords: cognitive; aspirin; warfarin; cardiovascular; antithrombotic A growing body of evidence suggests an association between cardiovascular risk factors and cognitive impairment during aging. These risk factors include hypertension, diabetes, hypercholesterolaemia, and cardiac disease such as atrial fibrillation and angina, all of which may promote neuropathological changes resulting from microthromboses in cerebral blood vessels. Antithrombotic medication may therefore protect cognitive function. In a randomised placebo controlled trial, Meyer et alI found that aspirin improved cognitive function in patients with multi-infarct dementia. Little is known, however, about the effect of antithrombotic medication on cognitive function in those without frank dementia. Population based studies have either reported no association2 or a modest trend towards protection of cognitive function3 from medication (non-steroidal anti-inflammatory drugs and aspirin). However, these authors relied on recall of use of medication and, in both studies, employed a single, global measure of current cognitive status.
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In the present study we measured cognitive function in patients already enrolled in a double blind placebo controlled factorial trial of low dose aspirin and low intensity oral anticoagulation with warfarin for their effect on the prevention of coronary and cerebral thrombosis. The purpose was to assess whether those who were on active treatment showed differences in cognitive performance compared with those who were receiving placebo. Because this cognitive study was conducted after the trial was already in progress, no baseline cognitive test data are available for comparison. Nevertheless, we were able to take advantage of the randomised design and detailed monitoring during a five year interval. The content of our neuropsychological test battery was based on studies that reported an association between cardiovascular risk factors and impairments in memory, attention, and abstract reasoning. 4 ( which has a large variance) is of potential functional significance for subjects in the age group of those in the present study.9 A sample of 350 subjects was estimated to be necessary to detect this effect with a power of 90% at a 5% level of significance. Of 1001 subjects originally meeting the above criteria, 493 had either already completed the TPT study or were no longer participating. Morbidity data, including causes of adverse events and death, will be available at the end of the TPT study. Of the remaining 508 eligible subjects, 60 were in practices where training for the neuropsychological tests could not be arranged and 24 subjects declined to be tested (nine in the P group, six in the A group, six in Table 1 shows the baseline characteristics for subjects in the four treatment groups who underwent cognitive testing.
There were no significant differences in age, education, body mass index, systolic or diastolic blood pressure, number of cigarettes smoked per day, plasma cholesterol, plasma fibrinogen, ECG, ischaemia, or family history of heart disease. Nor was there any difference between the groups in duration in the trial at the time of cognitive testing. Subjects in the placebo group had a slightly higher factor VII activity level at baseline compared with subjects in the active treatment groups (P = 0-04). There were no significant differences in these baseline characteristics between subjects who underwent cognitive testing and those from the original pool of 1001 who would have been eligible for cognitive testing.
COGNITIVE FUNCTION AND ANTITHROMBOTIC MEDICATION
Subjects were first grouped into those receiving placebo only and those on any active medication (WA, A, or W). placebo only for animal naming (F = 4-51, P = 0 034) and trailmaking part B-A (F = 6-06, P = 0.014).
EFFECT OF SPECIFIC REGIMES
MANOVA was then used to compare cognitive function in the four separate treatment groups. Univariate F tests showed a significant group effect for WAIS-R Similarities (F = 2-64, P = 0-049), with poorest performance in the W group. However, as Hotelling's T2 test was not significant, the possibility that this was a type I error cannot be ruled out.
These analyses suggested the possibility of better cognitive performance by patients taking aspirin than in patients taking warfarin. Table 3 therefore shows the results for all those taking aspirin (WA and A) compared with those not taking aspirin (W and P) and for all those taking warfarin (WA and W) compared with those not taking warfarin (A and P)-that is, a factorial design for separate treatment effects.
In the comparison according to warfarin allocation, several test scores were, if anything, poorer in those on active warfarin than with those who were not, significantly so for similarities (F = 5 49, P = 0-02), although, once again, Hotelling's T' test was not significant. There was no significant difference in the trailmaking B-A score between subjects with and without a family history of cardiovascular disease.
Discussion
As part of a double blind factorial trial of the effect of antithrombitic medication on the prevention of coronary heart disease we found that 405 of the older subjects who had been taking low dose or low intensity antithrombotic medication with warfarin, or aspirin, or both for about five years showed better cognitive performance than subjects given only placebo. We found this trend in most cognitive scores. Any effect was probably mainly due to aspirin. More specifically, scores for animal naming (a test of verbal fluency) and part B-A of the trailmaking test were significantly better in subjects taking active medication. Both of these tests are effortful, require mental control and flexibiliy, and are thought to be under frontal control. The trailmaking tests require motor speed and visual scanning although these elements were controlled in part by subtracting part A from part B and were not, in any case, sensitive to medication in the cancellation test. Caution is necessary in interpreting the results of this or any other study that consists of a subgroup analysis within a trial that was designed for another purpose. Firstly, we did not measure cognitive function at baseline. The possibility that treatment might influence cognitive function was only raised after the trial had started. We have to assume that the groups were similar in cognitive function at baseline, which seems likely. They were well matched in other respects and there was no discernable difference between those cognitively tested and those potentially available but not tested. Secondly, cognitive tests were administered by nurses with no previous experience in neuropsychological testing. Nevertheless, they received structured training, were guided by written test protocols, and were in any case blind to the medication status of each patient. Thirdly, the effect of antithrombotic medication on cognitive function, although significant, was generally slight although we would argue, in line with Gorkin et al,9 that the effect for Part B-A of the trailmaking test (a difference of seconds between placebo and active treatment groups) is of functional significance.
Whereas it should be born in mind that variance for the cardiovascular risk factors was restricted in this sample, the striking absence of correlations between any of the risk factors and time to complete part B-A of the trailmaking test was unexpected and brings into question the starting hypothesis of a vascular explanation for the wide range of scores found. Aspirin in the thrombosis prevention trial is low dose, 75 mg daily, and in a controlled release formulation designed for a prehepatic effect by reducing thromboxane in the platelets themselves while sparing prostacyclin production in the systemic vasculature after the liver metabolism of aspirin to salicylate, which is only weakly active.'7 If aspirin does preserve cognitive function, it may perhaps do so through some pathway other than its effect on platelets and thrombogenesis, in which case a higher dose than the 75 mg used in the thrombosis prevention trial and in a formulation subject to less extensive first pass metabolism in the liver might result in a larger benefit. Further investigations of the association between antithrombotic medication and cognitive function are warranted. 
